Abstract: Compositions and methods are disclosed for improving the effectiveness of a chemotherapeutic regimen to eradicate multidrug-resistant transformed cells from the body of a mammal, preferably from the body of a human. The present disclosure capitalizes on the discovery of a novel multidrug-resistance associated protein (MRP), herein designated MRP-.beta.. The disclosed compositions include MRP-.beta. nucleic acids, including probes and antisense oligonucleotides, MRP-.beta. polypeptides and antibodies, MRP-.beta. expressing host cells, and non-human mammals transgenic or nullizygous for MRP-.beta.. The disclosed methods include methods for attenuating aberrant MRP-.beta. gene expression, protein production and/or protein function. In addition, methods are disclosed for identifying and using a modulator, such as an inhibitor, of MRP-.beta.. Preferably, the modulator is a small molecule.

Abstract: This invention provides for nucleic acids encoding immunotoxins comprising a Pseudomonas exotoxin (PE) that does not require proteolytic activation for cytotoxic activity attached to an Fv antibody fragment having a variable heavy chain region bound through at least one disulfide bond to a variable light chain region. The combination of a "disulfide-stabilized" binding agent fused to a PE that does not require proteolytic activation provides an immunotoxin having surprising cytotoxic activity.

Abstract: Peptide compositions which inhibit the binding of one protein to another protein, and corresponding methods of use are disclosed. These peptide compositions include at least one peptide which binds to one protein, and at least one peptide which binds to the other protein. In the preferred embodiment, the peptide composition is composed of a combination of cyclic ICAM-1-based and LFA-1-based peptides which inhibit the binding of LFA-1 to ICAM-1. Such LFA-1/ICAM-1-based peptide compositions can be used to treat disease states such as rejection of transplanted organs, allergies, and autoimmune diseases.

Abstract: The invention provides two new human membrane fusion proteins (SYTAX1 or SYTAX2) and polynucleotides which identify and encode SYTAX1 or SYTAX2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of SYTAX1 or SYTAX2.

Abstract: Fusions of the transcription factor E2F and the retinoblastoma protein RB are provided, along with methods of treatment of hyperproliferative diseases.

Abstract: Sucrose ester and ether products, useful as food or beverage bulking agents, reduced calorie sweeteners, fat replacement agents, stabilizing agents, thickening agents and emulsifying agents; adhesives; biodegradable plastics and films; sizing agents for paper and textiles; ethical pharmaceuticals and new fibers are prepared by using a two-phase reaction system in which sucrose is dissolved in an alkaline, aqueous solution and an acidic reagent such as a bifunctional acid dichloride or epoxide is added to the sucrose in a water-immiscible organic solvent. Several types of products are produced: water-insoluble sucrose ester (ether) copolymers; water-soluble sucrose ester (ether) copolymers; sucrose ester (ether) dimers; and intramolecular, cyclic sucrose esters (ethers). These products can be further varied by using different kinds of acid dichlorides or epoxides that contain different kinds of functional groups.

Abstract: Monoclonal antibodies (MAb) are provided which have binding specificity to an antigen expressed on osteogenic and fibroblastic cells (OFA) and are capable of binding to osteogenic and fibroblastic cells at a substantially higher extent as compared to their binding to skin fibroblasts and stromal adipocytes. Also provided is a novel osteogenic and fibroblastic antigen (OFA) which is expressed on osteogenic and fibroblastic cells at a higher level than its expression in skin fibroblasts and stromal adipocytes having a molecular weight of about 80 kD as determined by western blotting or immunoprecipitation. The OFA and anti-OFA-MAbs are useful in the diagnosis and treatment of various hone related conditions.

Abstract: This invention relates to a method of detecting and diagnosing neurological disease or dysfunction using antibodies against a neurological form of Pancreatic Thread Protein (nPTP). Specifically, this invention is directed to a method of diagnosing Alzheimer's Disease, Down's Syndrome, and other neurological diseases or dysfunctions by using monoclonal antibodies, combination of those monoclonal antibodies or nucleic acid probes, to detect nPTP. The invention also relates to a recombinant DNA molecule encoding PTP and to the substantially pure form of nPTP. The invention additionally relates to a method of diagnosing pancreatic disease using antibodies against Pancreatic Thread Protein.

Abstract: The present invention discloses novel proteins which are dimers and multimers of single chain polypeptides. The single chain polypeptides having two domains derived from the immunoglobulin superfamily which are joined by a peptide linker. The dimers and multimers being formed by non-covalent linking of the single chain polypeptides.

Abstract: The invention relates to a plasma derived immunoglobulin G concentrate and to the process for producing said concentrate. The process comprises a series of chromatographic separations but no ethanol precipitation. The process also includes a viral inactivation treatment. The invention relates to the immunoglobulin G concentrate obtained by said process which is of therapeutic quality suitable for any use especially for intraveinous injection.

Abstract: This invention relates to methods of isolating hepatoblasts utilizing panning techniques and fluorescence activated cell sorting. This invention further relates to isolated hepatoblasts and to a method of treating liver dysfunction as well as to methods of forming artificial livers.

Abstract: This invention relates to a denture adhesive composition comprising a lower alkyl vinyl ether-maleic acid, anhydride, or salt polymer or mixtures thereof, one or more metallic salts, nonionically associated with the lower alkyl vinyl ether-maleic acid, anhydride, or salt polymer, and at least one non-adhesive self-supporting layer. This invention may also comprise other adhesive components.

Abstract: Methods for treatment of a subject with therapeutic or diagnostic agents by delivery of the therapeutic or diagnostic agents to the subject via sublytic amounts of terminal complement membrane attack acomplex (MAC) transmembrane channels are described. Also described are methods for delivery of therapeutic or diagnostic agents to cells in vitro via sublytic amounts of MAC transmembrane channels. Pharmaceutical preparations containing MAC transmembrane channel forming agents and kits for the formation of sublytic amounts of MAC transmembrane channels also are provided.

Abstract: The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of immunoglobulin E (IgE), direct equivalents and derivatives of said antibodies. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy.

Abstract: Moisturizing liquid personal cleansing emulsion compositions which comprise a moisturizing phase and an aqueous cleansing phase are disclosed. The moisturizing phase comprises from about 1% to about 30% by weight of the composition of lipophilic skin moisturizing agents comprised of droplets having a particle size distribution such that at least about 10% by weight of the droplets have a diameter of at least about 200 microns. The aqueous cleansing phase comprises from about 0.1% to about 10% by weight of the composition of a stabilizer, from about 5% to about 30% by weight of the composition of a lathering surfactant, and water. The liquid personal cleansing emulsion compositions contain less than about 5% by weight of fatty acid soap.

Abstract: Disclosed is human lactoferrin expressed using recombinant DNA, its method of production and purification.

Abstract: An anti-idiotypic monoclonal antibody that is specific against the N-glycolyl residues of gangliosides, particularly those expressed by cancer cells. The monoclonal antibody is useful as an immunomodulator for cancer treatment. Specifically, the anti-idiotype monoclonal antibody of the present invention is capable of inducing a predominant anti-idiotypic response in xenogeneic models. The anti-idiotypic monoclonal antibody also exerts a protective effect against malignant tumors in animals.

Abstract: The present invention relates to a novel hybridoma cell line which secretes monoclonal antibodies capable of binding to the AT.sub.1 subtype of the Angiotensin II receptor. It also relates to monoclonal antibodies secreted by the hybridoma, which antibodies may be used in diagnostic test kits as well as having therapeutic applications.

Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2D6 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2D6 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful in methods for screening drugs for metabolism by cytochrome P450 2D6, and in methods of screening individuals for a poor metabolizing human P450 2D6 phenotype.

Abstract: A method for treating a tumor is provided, which comprises the steps of preliminarily immunizing a patient in need of antitumor treatment with a toxin or toxin surrogate vaccine in an amount which is effective to generate an immune response to the toxin in the patient, thereby providing systemic protection from the toxin to the patient, and subsequently administering the toxin to the patient in an amount which is effective to kill tumor cells. The toxin may be any suitable toxin, for example ricin, abrin, gelonin or diphtheria.